Last $23.96 USD
Change Today -0.03 / -0.13%
Volume 208.9K
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

foundation medicine inc (FMI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - $45.00
52 Week Low
10/1/14 - $18.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

foundation medicine inc (FMI) Related Bloomberg News

View More Bloomberg News

foundation medicine inc (FMI) Related Businessweek News

View More BusinessWeek News

foundation medicine inc (FMI) Details

Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. The company offers clinical products, such as FoundationOne for solid tumors; and FoundationOne Heme, for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers. It has strategic collaboration agreement with WuXi PharmaTech (Cayman) Inc. to provide genomic profiling to biopharmaceutical companies conducting clinical trials. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts.

186 Employees
Last Reported Date: 03/7/14
Founded in 2009

foundation medicine inc (FMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $403.9K
Chief Operating Officer
Total Annual Compensation: $336.8K
Chief Medical Officer
Total Annual Compensation: $342.5K
Senior Vice President and General Counsel
Total Annual Compensation: $178.5K
Total Annual Compensation: $330.0K
Compensation as of Fiscal Year 2013.

foundation medicine inc (FMI) Key Developments

Foundation Medicine, Inc.(NasdaqGS:FMI) added to NASDAQ Biotechnology Index

Foundation Medicine, Inc. will be added to the NASDAQ Biotechnology Index.

Foundation Medicine, Inc. Announces New Clinical Data Supports Use of FoundationOne® Heme to Enable Informed Treatment Decisions in Wide Range of Hematologic Malignancies

Foundation Medicine, Inc. announced new data demonstrating that FoundationOne® Heme, developed in collaboration with Memorial Sloan Kettering Cancer Center, provides critical genomic information that can impact prognosis, influence therapeutic strategy and even refine conventional pathologic diagnosis in patients with a wide range of hematologic malignancies. Collectively, these data highlight the potentially transformative impact of FoundationOne Heme across all aspects of cancer care. These findings were presented in two posters and an oral presentation at the American Society of Hematology Annual Meeting in San Francisco. FoundationOne Heme is a comprehensive genomic profile that analyzes DNA of 405 genes and RNA of 265 genes that are most commonly altered in hematologic malignancies and sarcomas. The test was commercially launched in 2013, and is designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer.

Foundation Medicine, Inc. Appoints David J. Daly as Chief Commercial Officer

Foundation Medicine, Inc. announced the appointment of David J. Daly to the role of chief commercial officer. Mr. Daly will report to president and chief executive officer, Michael J. Pellini, M.D. Daly served most recently as vice president, commercial operations, Anatomic Pathology Division at Thermo Fisher Scientific. In this role, he led all global commercial activities including sales, marketing, and client and field services.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMI:US $23.96 USD -0.03

FMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $7.17 USD +0.05
NeoGenomics Inc $4.15 USD +0.12
Response Genetics Inc $0.30 USD -0.0677
Rosetta Genomics Ltd $2.33 USD -0.02
Sequenom Inc $3.73 USD +0.14
View Industry Companies

Industry Analysis


Industry Average

Valuation FMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FOUNDATION MEDICINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at